Prima BioMed Announces First Safety, Pharmacokinetics and Immuno-Monitoring Data From Phase IIb Clinical Trial of IMP321
June 21, 2016 20:31 ET
|
Prima BioMed Ltd
SYDNEY, AUSTRALIA--(Marketwired - Jun 21, 2016) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD), a leading immuno-oncology company, is pleased to announce initial safety data from the first cohort of...
Prima BioMed to Maintain NASDAQ Listing
June 06, 2016 21:23 ET
|
Prima BioMed Ltd
SYDNEY, AUSTRALIA--(Marketwired - Jun 6, 2016) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) the "Company" has received notification from the Listing Qualifications Department of the NASDAQ Stock...
Prima BioMed Enters Into Sale and Licensing Agreement With Sydys to Advance CVac(TM) Program
May 12, 2016 04:25 ET
|
Prima BioMed Ltd
SYDNEY, AUSTRALIA and SEATTLE, WA--(Marketwired - May 12, 2016) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD)
Sydys Licenses Clinical-Stage Immuno-oncology Assets in...
Japanese Patent Grants for IMP321 in Cancer
May 01, 2016 20:00 ET
|
Prima BioMed Ltd
SYDNEY, AUSTRALIA--(Marketwired - May 1, 2016) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) ("Prima", the "Company") announces the granting of patent number 5908210 entitled "Use of Recombinant...
IMP321 Safety and Immune Monitoring Data Published in Clinical Cancer Research Journal
March 15, 2016 03:40 ET
|
Prima BioMed Ltd
SYDNEY, AUSTRALIA--(Marketwired - Mar 15, 2016) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) advises that safety and immune monitoring data from an investigator-led clinical trial in melanoma using...
Prima BioMed Receives NASDAQ Notice of Bid Price Deficiency
March 04, 2016 01:32 ET
|
Prima BioMed Ltd
SYDNEY, AUSTRALIA--(Marketwired - Mar 4, 2016) - Prima BioMed Ltd (NASDAQ: PBMD) (ASX: PRR) ("Prima," the "Company"), has received notification from the Listing Qualifications Department of The...
Prima BioMed and WuXi Biologics Announce First Dose of Chinese-Manufactured Biologic in EU Clinical Trial
March 02, 2016 01:05 ET
|
Prima BioMed Ltd.
SHANGHAI, CHINA and SYDNEY, AUSTRALIA--(Marketwired - Mar 2, 2016) - Prima BioMed Ltd. (ASX: PRR) (NASDAQ: PBMD)
Highlights
First-Ever Chinese-Manufactured...
US Patent Grants for IMP731 Antibody
January 27, 2016 18:00 ET
|
Prima BioMed Ltd
SYDNEY, AUSTRALIA--(Marketwired - Jan 27, 2016) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) ("Prima", the "Company") announces the granting of patent number US 9,244,059 entitled "Cytotoxic...
Prima BioMed Initiates Phase I Melanoma Study in Australia
January 26, 2016 17:50 ET
|
Prima BioMed Ltd
SYDNEY, AUSTRALIA--(Marketwired - Jan 26, 2016) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD), a leading immuno-oncology company, is pleased to announce the initiation of the first clinical trial...
Prima BioMed Initiates Phase IIb Study in Metastatic Breast Cancer
December 22, 2015 07:00 ET
|
Prima BioMed Ltd
SYDNEY, AUSTRALIA--(Marketwired - Dec 22, 2015) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD)
Institutional Review Board Approval Now Obtained at Four Clinical Sites in...